Accueil > Actualité

La spin off DUALTPHARMA de l’Université de Maastricht développe au stades pré-clinique/clinique 1 des composés mis au point par Jean-Yves Winum (MCF de l’Université Montpellier 2) au sein de l’équipe Glycochimie et Reconnaissance Moléculaire. Cliquez ICI pour visionner la vidéo

« New class of dual drugs for cancer treatment »

par corneille - publié le , mis à jour le

La spin off DUALTPHARMA de l'Université de Maastricht développe au stades pré-clinique/clinique 1 des composés mis au point par Jean-Yves Winum (MCF de l'Université Montpellier 2) au sein de l'équipe Glycochimie et Reconnaissance Moléculaire. Cliquez ICI pour visionner la vidéo

Responses to current cancer treatments such as radiotherapy, surgery and/or chemotherapy remain generally unpredictable due to the heterogeneous nature of tumors and because in many cases hypoxic tumor (stem) cells escape from treatment. Besides, available treatments cause serious side effects since they attack healthy cells as well as cancerous cells. Another bottleneck is that most drugs are currently administered intravenously which requires hospital visits and increases the costs of administration.

We have shown that Carbonic anhydrase IX-specific dual drugs are able to reduce the hypoxic induced extracellular acidosis, have a therapeutic effect on their own and can sensitize tumors to irradiation & chemotherapy - specifically in tumors expressing CA IX. Pharmacological inhibition of CA IX expression alone, or in combination with doxorubicin and radiotherapy, will result in a therapeutic effect without causing normal tissue toxicity. Carbonic Anhydrase IX is present in 70% of all solid cancer and its expression has been associated with poor prognosis, tumor progression and aggressiveness. The objective is to focus on a frequent cancer : Non Small Cell Lung Cancer and an orphan indication : Small Cell Lung Cancer.

DualTPharma, a spin-off company of Maastricht UMC + has obtained the exclusive rights for commercialising the technology - originating from three leading universities (University of Maastricht, University of Montpellier and University of Florence) - and is well-positioned for taking the drugs through Phase II testing.

Pr. Philippe Lambin, Maastro Clinic, University of Maastricht, The Netherlands

Dr. Jean-Yves Winum, Institut des Biomolécules Max Mousseron UMR 5247 CNRS, ENSCM, University of Montpellier, France

Pr. Claudiu Supuran, University of Florence, Italy

References :

1- Cancer Targeting using carbonic anhydrase isoform IX inhibitors : P. Lambin, L. Dubois, C.T. Supuran, J-Y Winum, EP 2655336 ; WO2012087115 (A1).

2- Rami M, Dubois L, Parvathaneni NK, Alterio V, van Kuijk SJ, Monti SM, Lambin P, De Simone G, Supuran CT, Winum JY. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J Med Chem. 2013, 56(21) : 8512-20.

3- Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, Biemans R, Rami M, Parvathaneni NK, Vullo D, Vooijs M, Supuran CT, Winum JY, Lambin P. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation : a new concept of dual targeting drugs. Radiother Oncol. 2013, 108(3):523-8.